You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

advanced EGFR-positive

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Patients With Advanced EGFR Positive Non-Small Cell Lung Cancer

Recruiting
  • Lung Cancer Non-small Cell Stage IV
    • Athens, Greece
      Hellenic Cooperative Oncology Group
    Nov 14, 2022

    Solid Tumor, Adult, EGFR Overexpression Trial in Beijing (TGFßR-KO CAR-EGFR T Cells)

    Recruiting
    • Solid Tumor, Adult
    • EGFR Overexpression
    • TGFβR-KO CAR-EGFR T Cells
    • Beijing, Beijing, China
      Chinese PLA General Hospital
    Mar 25, 2022

    Advanced EGFR Positive Solid Tumor Trial in China, United States (ZZ06)

    Recruiting
    • Advanced EGFR Positive Solid Tumor
    • ZZ06
    • Los Angeles, California
    • +3 more
    Mar 7, 2022

    NSCLC Trial in Shanghai (IN10018, Furmonertinib)

    Recruiting
    • NSCLC
    • Shanghai, China
      Shanghai Pulmonary Hospital
    Aug 8, 2023

    Osimertinib for Advanced EGFR-positive NSCLC Patients

    Recruiting
    • EGFR Positive Non-small Cell Lung Cancer
    • Non Small Cell Lung Cancer
      • Singapore, Singapore
        National University Hospital
      Aug 31, 2021

      Lung Cancer, TKI Resistance, EGFR Sensitive Mutation Trial (Anlotinib, Penpulimab)

      Not yet recruiting
      • Lung Cancer
      • +4 more
      • (no location specified)
      Sep 15, 2023

      Advanced Solid Tumors Trial in Guangzhou, Changsha (MRG003+HX008)

      Recruiting
      • Advanced Solid Tumors
      • Guangzhou, Guangdong, China
      • +1 more
      Jan 15, 2023

      EGFR/ B7H3-positive Advanced Lung Cancer, EGFR/ B7H3-positive Advanced Triple-negative Breast Cancer Trial in Guangzhou

      Recruiting
      • EGFR/ B7H3-positive Advanced Lung Cancer
      • EGFR/ B7H3-positive Advanced Triple-negative Breast Cancer
      • EGFR/B7H3 CAR-T
      • Guangzhou, Guangdong, China
        Second Affiliated Hospital of Guangzhou Medical University
      Apr 18, 2022

      Real-world Data of Afatinib Treatment in First-line Setting and

      Active, not recruiting
      • Non-squamous, Non-Small Cell Lung Cancer
      • Tokyo, Japan
        Nippon Boehringer Ingelheim Co., Ltd.
      Jan 9, 2023

      EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among

      Recruiting
      • Lung Cancer
      • Kuala Lumpur, Malaysia
      • +2 more
      Nov 21, 2022

      NSCLC, EGFR G719X, EGFR L861Q Trial in Chongqing (Furmonertinib 160 mg, Q.D.)

      Recruiting
      • Non-small Cell Lung Cancer
      • +3 more
      • Furmonertinib 160 mg, Q.D.
      • Chongqing, Chongqing, China
      • +2 more
      Sep 16, 2022

      Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7

      Active, not recruiting
      • Metastatic Lung Non-Small Cell Carcinoma
      • +5 more
      • Laboratory Biomarker Analysis
      • +3 more
      • New Haven, Connecticut
      • +4 more
      Jan 27, 2023

      NSCLC Stage III, EGFR Positive NSCLC, Non-squamous Non-small-cell Lung Cancer Trial in Korea, Republic of (Lazertinib)

      Recruiting
      • Non-small Cell Lung Cancer Stage III
      • +2 more
      • Busan, Korea, Republic of
      • +12 more
      Jan 17, 2023

      NSCLC Trial in Spain, United Kingdom, United States (Lazertinib)

      Completed
      • Carcinoma, Non-Small-Cell Lung
      • Duarte, California
      • +8 more
      Jan 31, 2023

      Observes Afatinib as First-line Treatment and Sequential Therapy

      Active, not recruiting
      • Non-squamous, Non-Small Cell Lung Cancer
      • Beijing, China
      • +9 more
      Jan 9, 2023

      Lung Cancer, Non-small Cell, EGFR Gene Mutation, EGFR-TKI Resistant Mutation Trial in Changsha (Genomic profiles detection,

      Recruiting
      • Lung Cancer, Non-small Cell
      • +4 more
      • Genomic profiles detection
      • circulating tumor DNA detection
      • Changsha, Hunan, China
        Department of Oncology, The Second Xiangya Hospital, Central Sou
      Oct 25, 2022

      Non-Small Cell Lung Carcinoma Trial in Duarte, Stanford, Nashville (drug, biological, other)

      Terminated
      • Non-Small Cell Lung Carcinoma
      • Duarte, California
      • +2 more
      Apr 6, 2022

      PD-1 Antibody Plus Chemotherapy for TKI Failure Driver Gene

      Recruiting
      • Non Small Cell Lung Cancer
        • Changsha, Hunan, China
          Yongchang Zhang
        Mar 9, 2022

        NSCLC Trial (30 µg OBI-833/100 µg OBI-821, Erlotinib (150 mg daily))

        Not yet recruiting
        • Non-small Cell Lung Cancer
        • 30 μg OBI-833/100 μg OBI-821
        • Erlotinib (150 mg daily)
        • (no location specified)
        Jun 28, 2022

        Locally Advanced or Metastatic NSCLC Patients, Progressed From

        Active, not recruiting
        • Locally Advanced or Metastatic NSCLC
          • Beijing, China
          • +16 more
          Dec 16, 2022

          EGFR Positive NSCLC Trial in Goyang-Si (Erlotinib plus Bevacizumab, Erlotinib)

          Active, not recruiting
          • EGFR Positive Non-small Cell Lung Cancer
          • Goyang-Si, Gyeonggi-do, Korea, Republic of
            National Cancer Center
          Apr 4, 2022

          Malignant Tumor of Lung, Poor Performance Status Trial in Guangzhou (Almonertinib)

          Recruiting
          • Malignant Tumor of Lung
          • Poor Performance Status
          • Guangzhou, Guangdong, China
            Zhou Chengzhi
          Apr 12, 2023

          Breast Cancer Trial in Switzerland (anti-EGFR-IL-dox)

          Terminated
          • Breast Cancer
          • Aarau, Switzerland
          • +14 more
          Sep 27, 2021

          NSCLC Stage IIIB, NSCLC Stage IIIC, NSCLC Stage IV Trial in Worldwide (Dacomitinib)

          Active, not recruiting
          • NSCLC Stage IIIB
          • +4 more
          • Hong Kong, Hong Kong
          • +8 more
          Jan 10, 2023

          NSCLC Trial in Shanghai (TY-9591(10mg,40mg) qd. po)

          Recruiting
          • NSCLC
          • TY-9591(10mg,40mg) qd. po
          • Shanghai, China
            Shanghai Chest Hospital
          Nov 7, 2021